

a therapeutically effective amount of a corticosteroid selected from the group consisting of mometasone and pharmacologically acceptable salts, esters and derivatives thereof.

AI 52. (Amended) The method of claim 51, wherein the formulation is administered via oral inhalation.

53. (Amended) The method of claim 51, wherein the formulation is administered via nasal inhalation.

54. (Amended) The method of claim 51, wherein the formulation is administered on an as-needed basis.

Also add new claims 75-116 as indicated in Appendix A.

REMARKS

In the Office Action, the Examiner required restriction between the following two groups of claims: Group (I), claims 1-50, and 56-74, directed to a pharmaceutical formulation, drug delivery system, and dosage form; and Group (II), claims 51-55, directed to a method for treating a patient suffering from a condition, disease or disorder that is responsive to treatment with a bronchodilator/corticosteroid combination. The Examiner has also requested an election of species with respect to the active agents recited in claim 51.

With this response, claims 51-54 have been amended, nonelected claims 1-50 and 56-74 have been canceled, and new claims 75-116 have been added. Please note that cancellation of claims 1-50 and 56-74 is without prejudice and without intent to abandon any originally claimed subject matter.

Accordingly, claims 51-55 and 75-116 are now pending (see Appendix B).

RESPONSE AND ELECTION:

In response to the restriction requirement, applicants elect the claims of Group (II), claims 51-55, without traverse. With regard to the requirement for election of species, applicants elect as follows:

corticosteroid: mometasone and esters thereof;

bronchodilator: pirbuterol and acid addition salts thereof.

Claims 51-80 and 84-116 read on the elected species.